MBRX
Moleculin Biotech, Inc.
Key Financials
Net Income
$-33560000
↓ 54.2%
Revenue
$0
NaN%
Total Assets
$22.1M
↑ 30.7%
Total Liabilities
$7.1M
↓ 35.0%
Operating Income
$-25103000
↑ 5.8%
Cash & Equivalents
$8.9M
↑ 107.5%
Shareholders' Equity
$15.0M
↑ 151.0%
Operating Cash Flow
$-22735000.00
↑ 4.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| PRE 14A | 8/14/2026 | View on SEC |
| 8-K | 8/14/2026 | View on SEC |
| 10-Q | 8/13/2026 | View on SEC |
| SCHEDULE 13G | 8/10/2026 | View on SEC |
| SCHEDULE 13G | 8/6/2026 | View on SEC |
| 4 | 8/5/2026 | View on SEC |
| 4 | 8/5/2026 | View on SEC |
| 4 | 8/5/2026 | View on SEC |
| 8-K | 8/3/2026 | View on SEC |
| 424B5 | 8/3/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | MBRX |
| Company Name | Moleculin Biotech, Inc. |
| CIK | 1659617 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 713-300-5160 |